| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total research and development | NaN | 2,845,282 | 6,495,677 | NaN |
| General and administrative | NaN | 5,310,422 | 1,130,764 | NaN |
| Other income, net | NaN | 43,254 | 39,088 | NaN |
| Change in fair value of convertible promissory notes | NaN | 0 | -365,718 | NaN |
| Change in fair value of convertible promissory notes | NaN | 0 | NaN | NaN |
| Net loss | -2,541,070 | -8,112,450 | -2,975,117 | -9,761,349 |
| Accounts payable and other current liabilities | NaN | NaN | -249,952 | 1,334,030 |
| Stock-based compensation | 227,180 | 785,814 | 150,614 | 421,654 |
| Change in fair value of convertible promissory notes | NaN | NaN | 365,718 | 787,703 |
| Warrant repricing | 410,154 | NaN | NaN | NaN |
| Prepaid expenses and other current assets | -119,319 | -203,386 | 357,997 | -821,899 |
| Depreciation | NaN | NaN | NaN | 0 |
| Accounts payable and other current liabilities | -5,225,576 | 2,848,858 | NaN | NaN |
| Operating lease right-of-use asset and liability, net | NaN | -199 | -597 | -1,193 |
| Net cash used in operating activities | -7,009,993 | -3,190,513 | -2,567,427 | -9,065,316 |
| Proceeds from issuance of convertible promissory notes | NaN | 0 | 0 | 5,714,800 |
| Proceeds from issuance of shares of common stock and warrants | NaN | 0 | 2,339,169 | 4,057,719 |
| Proceeds from issuance of preferred stock | NaN | 6,000,000 | NaN | NaN |
| Proceeds from exercise of pre-funded warrants | NaN | 1,754 | 154 | NaN |
| Issuance costs | NaN | 129,252 | 103,958 | 336,255 |
| Net cash provided by financing activities | NaN | 5,872,502 | 2,235,365 | 9,436,264 |
| Net change in cash and cash equivalents | -7,009,993 | 2,681,989 | -332,062 | 370,948 |
| Cash and cash equivalents, beginning of period | 8,507,628 | 5,825,639 | 5,786,753 | NaN |
| Cash and cash equivalents, end of period | 1,497,635 | 8,507,628 | 5,825,639 | NaN |
Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc. (INDP)